Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Issue 1 (January 2019) - Aboud, M.; Kaplan, R.; Lombaard, J.; Zhang, F.; Hidalgo, J.; Mamedova, E.; Losso, M.; Chetchotisakd, P.; Brites, C.; Sievers, J.; Brown, D.; Hopking, J.; et al.